专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US07411045B2 Autocrine growth factor receptor antibodies and methods 有权
标题翻译：自分泌生长因子受体抗体及方法
公开(公告)号：US07411045B2
公开(公告)日：2008-08-12
申请号：US10298540
申请日：2002-11-19
申请人： Ginette Serrero , Le Sun
发明人： Ginette Serrero , Le Sun
IPC分类号： C07K16/00
CPC分类号： C07K14/475 , A61K38/00 , A61K2039/505 , C07K16/22 , C07K16/2863 , C07K2317/73 , C07K2317/76 , C12N2799/026 , G01N33/57484 , G01N33/6872
摘要： Disclosed herein are antitumor compositions and methods of interfering with the biological activity of PC cell derived growth factor (PCDGF), anti-PCDGF receptor antibodies, fragments thereof, and methods of making anti-PCDGF receptor antibodies. The methods involve inhibiting the proliferation of tumor cells expressing the PCDGF receptor by contacting the surface of the cell with anti-PCDGF receptor antibodies. Anti-PCDGF receptor antibodies are capable of binding to the surface of a cell and interfering with the binding of PCDGF to its receptor. Also provided are compositions comprising anti-PCDGF receptor antibodies and cytotoxic molecules (e.g., toxins, oncotoxins, mitotoxins, immunotoxins, and antisense oligonucleotides).
摘要翻译：本文公开了抗肿瘤组合物和干扰PC细胞来源的生长因子（PCDGF），抗PCDGF受体抗体及其片段的生物学活性的方法以及制备抗PCDGF受体抗体的方法。所述方法包括通过使细胞表面与抗PCDGF受体抗体接触来抑制表达PCDGF受体的肿瘤细胞的增殖。抗PCDGF受体抗体能够结合细胞表面并干扰PCDGF与其受体的结合。还提供包含抗PCDGF受体抗体和细胞毒性分子（例如毒素，毒毒素，线粒体蛋白，免疫毒素和反义寡核苷酸）的组合物。

2. 发明授权

US07183384B2 Monoclonal antibody 7H11 reactive with human cancer 有权
标题翻译：单克隆抗体7H11与人类癌症反应
公开(公告)号：US07183384B2
公开(公告)日：2007-02-27
申请号：US10793949
申请日：2004-03-08
申请人： Le Sun , Ginette Serrero , Joe Corvera , Yudong Hu
发明人： Le Sun , Ginette Serrero , Joe Corvera , Yudong Hu
IPC分类号： C07K16/00 , C12N5/06
CPC分类号： G01N33/5091 , C07K16/3015 , G01N33/5088 , G01N33/57484 , G01N2800/52
摘要： Novel monoclonal antibodies and binding fragments thereof specific to human breast cancer, lung cancer, colon cancer and other cancers. The monoclonal antibody does not bind to the cell surface of normal human tissues. The corresponding cancer-specific antigen with an apparent molecular weight of 150 kd and polynucleotides encoding the antigen and the CDR regions of the antibody are Also disclosed are methods for diagnosis, prognosis and treatment of human breast cancer. The antibodies have tumor specificity and are useful for therapy, diagnosis, monitoring, detecting and imaging of cancers. The antibody-recognized cancer-specific surface antigens can serve as targets for detecting, diagnosing, inhibiting or killing cancer cells.
摘要翻译：新型单克隆抗体及其对人乳腺癌，肺癌，结肠癌和其他癌症特异性的结合片段。单克隆抗体不结合正常人组织的细胞表面。具有150kd的相应的癌症特异性抗原和编码抗体的抗原和CDR区的多核苷酸还公开了用于诊断，预后和治疗人乳腺癌的方法。抗体具有肿瘤特异性，可用于癌症的治疗，诊断，监测，检测和成像。抗体识别的癌症特异性表面抗原可以作为检测，诊断，抑制或杀死癌细胞的靶标。

3. 发明授权

US07560095B2 Cancer specific monoclonal antibodies 有权
标题翻译：癌症特异性单克隆抗体
公开(公告)号：US07560095B2
公开(公告)日：2009-07-14
申请号：US10554321
申请日：2004-04-22
申请人： Le Sun , Ginette Serrero , Joe Corvera , Yudong Hou
发明人： Le Sun , Ginette Serrero , Joe Corvera , Yudong Hou
IPC分类号： A61K39/395 , C07K7/00
CPC分类号： G01N33/57488 , A61K2039/505 , C07K16/3015 , C07K16/3023 , C07K16/3038 , G01N33/57492 , G01N2800/52
摘要： Novel monoclonal antibodies and binding fragments thereof specific to human breast cancer, lung cancer, colon cancer and other cancers. The monoclonal antibody does not bind to the cell surface of normal human tissues. The corresponding cancer-specific antigen or antigens with an apparent molecular weight of 40-52 130-200 kDa and polynucleotides encoding the antigen and the CDR regions of the antibody are also disclosed, as well as methods for diagnosis, prognosis and treatment of human breast cancer. The antibodies have tumor specificity and are useful for therapy, diagnosis, monitoring, detecting and imaging of cancers. The antibody-recognized cancer-specific surface antigens can serve as targets for detecting, diagnosing, inhibiting or killing cancer cells.
摘要翻译：新型单克隆抗体及其对人乳腺癌，肺癌，结肠癌和其他癌症特异性的结合片段。单克隆抗体不结合正常人组织的细胞表面。还公开了具有40-52 130-200kDa的相应的癌症特异性抗原或抗原，以及编码抗体的抗原和CDR区的多核苷酸以及用于诊断，预后和治疗人乳腺的方法癌症。抗体具有肿瘤特异性，可用于癌症的治疗，诊断，监测，检测和成像。抗体识别的癌症特异性表面抗原可以作为检测，诊断，抑制或杀死癌细胞的靶标。

4. 发明申请

US20080311120A1 AUTOCRINE GROWTH FACTOR RECEPTOR ANTIBODIES AND METHODS 失效
标题翻译：自动生长因子生长因子受体抗体和方法
公开(公告)号：US20080311120A1
公开(公告)日：2008-12-18
申请号：US12142465
申请日：2008-06-19
申请人： Ginette Serrero , Le Sun
发明人： Ginette Serrero , Le Sun
IPC分类号： A61K39/395 , C07K16/30 , G01N33/574 , C12N5/02
CPC分类号： C07K14/475 , A61K38/00 , A61K2039/505 , C07K16/22 , C07K16/2863 , C07K2317/73 , C07K2317/76 , C12N2799/026 , G01N33/57484 , G01N33/6872
摘要： Disclosed herein are antitumor compositions and methods of interfering with the biological activity of PC cell derived growth factor (PCDGF), anti-PCDGF receptor antibodies, fragments thereof, and methods of making anti-PCDGF receptor antibodies. The methods involve inhibiting the proliferation of tumor cells expressing the PCDGF receptor by contacting the surface of the cell with anti-PCDGF receptor antibodies. Anti-PCDGF receptor antibodies are capable of binding to the surface of a cell and interfering with the binding of PCDGF to its receptor. Also provided are compositions comprising anti-PCDGF receptor antibodies and cytotoxic molecules (e.g., toxins, oncotoxins, mitotoxins, immunotoxins, and antisense oligonucleotides).
摘要翻译：本文公开了抗肿瘤组合物和干扰PC细胞来源的生长因子（PCDGF），抗PCDGF受体抗体及其片段的生物学活性的方法以及制备抗PCDGF受体抗体的方法。所述方法包括通过使细胞表面与抗PCDGF受体抗体接触来抑制表达PCDGF受体的肿瘤细胞的增殖。抗PCDGF受体抗体能够结合细胞表面并干扰PCDGF与其受体的结合。还提供包含抗PCDGF受体抗体和细胞毒性分子（例如毒素，毒毒素，线粒体蛋白，免疫毒素和反义寡核苷酸）的组合物。

5. 发明申请

US20070025911A1 Cancer specific monoclonal antibodies 有权
标题翻译：癌症特异性单克隆抗体
公开(公告)号：US20070025911A1
公开(公告)日：2007-02-01
申请号：US10554321
申请日：2004-04-22
申请人： Le Sun , Ginette Serrero , Joe Corvera , Yudong Hou
发明人： Le Sun , Ginette Serrero , Joe Corvera , Yudong Hou
IPC分类号： A61K51/00 , A61K39/395 , G01N33/574 , C07H21/04 , C12P21/06 , C07K16/30 , C07K16/46 , A61K36/47
CPC分类号： G01N33/57488 , A61K2039/505 , C07K16/3015 , C07K16/3023 , C07K16/3038 , G01N33/57492 , G01N2800/52
摘要： Novel monoclonal antibodies and binding fragments thereof specific to human breast cancer, lung cancer, colon cancer and other cancers. The monoclonal antibody does not bind to the cell surface of normal human tissues. The corresponding cancer-specific antigen or antigens with an apparent molecular weight of 40-52 130-200 kDa and polynucleotides encoding the antigen and the CDR regions of the antibody are also disclosed, as well as methods for diagnosis, prognosis and treatment of human breast cancer. The antibodies have tumor specificity and are useful for therapy, diagnosis, monitoring, detecting and imaging of cancers. The antibody-recognized cancer-specific surface antigens can serve as targets for detecting, diagnosing, inhibiting or killing cancer cells.
摘要翻译：新型单克隆抗体及其对人乳腺癌，肺癌，结肠癌和其他癌症特异性的结合片段。单克隆抗体不结合正常人组织的细胞表面。还公开了具有40-52 130-200kDa的相应的癌症特异性抗原或抗原，以及编码抗体的抗原和CDR区的多核苷酸以及用于诊断，预后和治疗人乳腺的方法癌症。抗体具有肿瘤特异性，可用于癌症的治疗，诊断，监测，检测和成像。抗体识别的癌症特异性表面抗原可以作为检测，诊断，抑制或杀死癌细胞的靶标。

6. 发明授权

US08088373B2 Autocrine growth factor receptor antibodies and methods 失效
标题翻译：自分泌生长因子受体抗体及方法
公开(公告)号：US08088373B2
公开(公告)日：2012-01-03
申请号：US12142465
申请日：2008-06-19
申请人： Ginette Serrero , Le Sun
发明人： Ginette Serrero , Le Sun
IPC分类号： A61K39/395
CPC分类号： C07K14/475 , A61K38/00 , A61K2039/505 , C07K16/22 , C07K16/2863 , C07K2317/73 , C07K2317/76 , C12N2799/026 , G01N33/57484 , G01N33/6872
摘要： Disclosed herein are antitumor compositions and methods of interfering with the biological activity of PC cell derived growth factor (PCDGF), anti-PCDGF receptor antibodies, fragments thereof, and methods of making anti-PCDGF receptor antibodies. The methods involve inhibiting the proliferation of tumor cells expressing the PCDGF receptor by contacting the surface of the cell with anti-PCDGF receptor antibodies. Anti-PCDGF receptor antibodies are capable of binding to the surface of a cell and interfering with the binding of PCDGF to its receptor. Also provided are compositions comprising anti-PCDGF receptor antibodies and cytotoxic molecules (e.g., toxins, oncotoxins, mitotoxins, immunotoxins, and antisense oligonucleotides).
摘要翻译：本文公开了抗肿瘤组合物和干扰PC细胞来源的生长因子（PCDGF），抗PCDGF受体抗体及其片段的生物学活性的方法以及制备抗PCDGF受体抗体的方法。所述方法包括通过使细胞表面与抗PCDGF受体抗体接触来抑制表达PCDGF受体的肿瘤细胞的增殖。抗PCDGF受体抗体能够结合细胞表面并干扰PCDGF与其受体的结合。还提供包含抗PCDGF受体抗体和细胞毒性分子（例如毒素，毒毒素，线粒体蛋白，免疫毒素和反义寡核苷酸）的组合物。

7. 发明申请

US20070196274A1 Immunoconjugates with improved efficacy for the treatment of diseases 审中-公开
标题翻译：具有改善治疗疾病功效的免疫缀合物
公开(公告)号：US20070196274A1
公开(公告)日：2007-08-23
申请号：US11655263
申请日：2007-01-19
申请人： Le Sun
发明人： Le Sun
IPC分类号： A61K51/00 , A61K39/395 , A61K39/42 , C07K16/10 , C07K16/12 , C07K16/18
CPC分类号： C07K16/1063 , A61K47/6841 , A61K47/6898 , A61K51/1006 , B82Y5/00 , C07K16/00
摘要： The invention provides therapeutic or diagnostic antibodies with modified N— or C-terminal sequences that are enriched with lysine or tyrosine residues. These lysine or tyfosine residues can be used to couple radioisotopes, cytotoxic agents, or detectable labels. The increased stoichiometric ratios of these agents in the antibody conjugates lead to improved therapeutic efficacy or enhanced detection sensitivity. Non-limiting examples of antibodies suitable for the present invention include anti-CD22, anti-ErbB2, anti-VEGF, anti-EGFR, anti-VEGFR, anti-Her-3, anti-Her-4, anti-CEA, anti-CTLA-4, anti-CD4, anti-CD3, anti-CD20, anti-TNF-a, anti-CD11a, anti-Lewis Y antigen, anti-TrailR, anti-IL2R, anti-CD30, anti-CD146, anti-CD147, anti-alpha V integrin beta, anti-CD19, anti-GD2, anti-3H11, anti-EBV, anti-HIV, anti-HBV, anti-HCV, and other disease-specific antibodies.
摘要翻译：本发明提供具有富含赖氨酸或酪氨酸残基的经修饰的N-或C-末端序列的治疗或诊断抗体。这些赖氨酸或酪氨酸残基可用于偶联放射性同位素，细胞毒性剂或可检测标记。这些试剂在抗体缀合物中的增加的化学计量比导致改进的治疗功效或增强的检测灵敏度。适用于本发明的抗体的非限制性实例包括抗CD22，抗ErbB2，抗VEGF，抗EGFR，抗VEGFR，抗Her-3，抗Her-4，抗CEA， CTLA-4，抗CD4，抗CD3，抗CD20，抗TNF-α，抗CD11a，抗Lewis Y抗原，抗TrailR，抗IL2R，抗CD30，抗CD146， CD147，抗αv整合素β，抗CD19，抗GD2，抗3H11，抗EBV，抗HIV，抗HBV，抗HCV等疾病特异性抗体。

8. 发明申请

US20100266620A1 Immunoconjugates for treatment of infectious diseases 审中-公开
标题翻译：用于治疗感染性疾病的免疫接种物
公开(公告)号：US20100266620A1
公开(公告)日：2010-10-21
申请号：US11655266
申请日：2007-01-19
申请人： Le Sun
发明人： Le Sun
IPC分类号： A61K39/395 , C07K16/08 , C07K16/10 , A61P31/12
CPC分类号： C07K16/1063 , A61K47/6841 , A61K47/6898 , A61K51/1006 , B82Y5/00 , C07K16/00
摘要： The present invention features immunoconjugates which comprise therapeutic agents coupled to antibodies that specifically recognize pathogen surface antigens. These immunoconjugates can be used to treat or prevent infectious diseases. Upon administration of an immunoconjugate of the present invention to an infected host, the immunoconjugate binds to a specific antigen on the surface of the targeted pathogen (e.g., virus). As the pathogen enters the host cells, the therapeutic agent(s) in the immunoconjugate destroys the infected host cells (and, preferably, the bound pathogen), thereby preventing the replication and transmission of the pathogen. In one embodiment, the immunoconjugates of the present invention specifically recognize surface/envelope antigens of the following viruses: HIV, HBV, HCV, EBV, influenza virus, and SARS associated coronavirus.
摘要翻译：本发明的特征在于免疫缀合物，其包含与特异性识别病原体表面抗原的抗体偶联的治疗剂。这些免疫缀合物可用于治疗或预防感染性疾病。当将本发明的免疫偶联物施用于被感染的宿主时，免疫缀合物与靶向病原体（例如病毒）的表面上的特异性抗原结合。当病原体进入宿主细胞时，免疫缀合物中的治疗剂破坏感染的宿主细胞（优选结合的病原体），从而防止病原体的复制和传播。在一个实施方案中，本发明的免疫缀合物特异性识别以下病毒的表面/包膜抗原：HIV，HBV，HCV，EBV，流感病毒和SARS相关冠状病毒。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式